aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Stock Information for aTyr Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About aTyr Pharma Inc.

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.